Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours (Q44712034)

5 December 2017

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours (English)

1 reference

5 December 2017

10

1 reference

5 December 2017

12

1 reference

5 December 2017

A Romer

1

1 reference

5 December 2017

D Seiler

2

1 reference

5 December 2017

N Marincek

3

1 reference

5 December 2017

P Brunner

4

1 reference

5 December 2017

M T Koller

5

1 reference

5 December 2017

Q K T Ng

6

1 reference

5 December 2017

H R Maecke

7

1 reference

5 December 2017

J Müller-Brand

8

1 reference

5 December 2017

C Rochlitz

9

1 reference

5 December 2017

C Schindler

11

1 reference

5 December 2017

2 October 2013

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

5 December 2017

1 reference

5 December 2017

41

1 reference

5 December 2017

2

1 reference

5 December 2017

214-222

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-013-2559-8

5 December 2017

0 references

cites work

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Chemotherapy and biotherapy in the treatment of neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Peptide receptors as molecular targets for cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Cancer: antitumor effects of octreotide LAR, a somatostatin analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

[(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Tutorial in biostatistics: competing risks and multi-state models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2559-8

Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

21 January 2018

1 reference

12 December 2020

DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy

1 reference

12 December 2020

Yttrium-90-labelled somatostatin-analogue for cancer treatment

1 reference

12 December 2020

Absorbed fractions for electrons and beta particles in spheres of various sizes

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin

1 reference

12 December 2020

10.1007/S00259-013-2559-8

Identifiers

DOI

1 reference

5 December 2017

1 reference